摘要
目的探讨益生菌辅助治疗对乙肝后肝硬化失代偿期患者肝功能和肠道黏膜通透性的影响。方法选取2015年12月—2018年6月我院收治的110例乙肝后肝硬化失代偿期患者,采用随机数字表法分为观察组(n=55)和对照组(n=55)。对照组患者接受常规治疗,观察组患者在常规治疗的基础上给予益生菌辅助治疗。观察两组患者治疗前后的肝功能和肠道黏膜通透性变化。结果(1)治疗后,两组患者的(ALT)、谷草转氨酶(AST)和总胆红素(TBIL)水平均显著降低,白蛋白(ALB)水平显著升高,组间比较差异有统计学意义(P <0.05)。(2)治疗后,两组患者的乳果糖(LAC)、甘露醇(MAN)和LAC/MAN均显著降低,组间比较差异有统计学意义(P <0.05)。结论益生菌辅助治疗能显著改善乙肝后肝硬化失代偿期患者肝功能和肠道黏膜通透性,效果显著。
Objective To investigate the effects of probiotics adjuvant therapy on liver function and intestinal mucosal permeability in patients with decompensated hepatitis B cirrhosis. Methods 110 patients with decompensated post-hepatitis B cirrhosis admitted to our hospital from December 2015 to June 2018 were randomly divided into observation group(n=55) and control group(n=55). Patients in the control group received routine treatment. Patients in the observation group were given probiotics on the basis of conventional treatment. The changes of liver function and intestinal mucosal permeability before and after treatment were observed. Results(1) After treatment, ALT, AST and TBIL levels were significantly lower in both groups, and ALB levels were lower. Significantly elevated, the difference between the groups was statistically significant(P<0.05). LAC, MAN and LAC/MAN were significantly lower in the two groups. The difference between the two groups was statistically significant(P<0.05). Conclusion Probiotics adjuvant therapy can significantly improve liver function and intestinal mucosal permeability in patients with decompensated liver cirrhosis after hepatitis B. The effect is significant and worthy of clinical application.
作者
付景
马金平
李诤
FU Jing;MA Jinping;LI Zheng(Department of Gastroenterology, Heze Municipal Hospital, Heze Shandong 274000, China)
出处
《中国继续医学教育》
2019年第10期136-137,共2页
China Continuing Medical Education
关键词
益生菌
乙肝
肝硬化失代偿期
肝功能
肠道黏膜通透性
临床对照研究
probiotics
hepatitis B
cirrhosis decompensation
liver function
intestinal mucosal permeability
clinical controlled study
